GSK share price is still undervalued dispite its strong financial performance. Over the last month, the pharmaceutical company's holdings increased by around $5 billion. Notable finance authorities, such as TD Cowen and Deutsche Bank, maintain a 'hold' rating on the stock, suggesting it has potential for growth. However, it's strategic decisions, such as the $500 million drug-development deal with China's Jiangsu Hengrui and share buyback program have aided in enhancing shareholder value. This program has seen a solid boost with multiple purchases of shares, including those by GSK executives under a reward plan.
On the innovation front, GSK has had its share of ups and downs. The company's stock took a hit when its blood cancer drug was headed for US rejection. Despite this, GSK's stock has risen. A major highlight was the FDA approval of Nucala for COPD and back rolling of Blenrep for cancer treatment. Despite this, the stock experienced a small weekly drop, along with other European stocks. On a positive note, the stock has risen around 17% year to date (YTD). Is it time to buy, sell or hold? Only time will tell.
GSK Stocks News Analytics from Wed, 05 Feb 2025 08:00:00 GMT to Sat, 06 Sep 2025 05:16:24 GMT - Rating 6 - Innovation 2 - Information 8 - Rumor -2
